MKMikhail V. Kalashnikov

Mikhail V. Kalashnikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mikhail V. Kalashnikov has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Ravidasvir – a pan-genotypic NS5A inhibitor for the treatment of chronic hepatitis C

    by P.O. Bogomolov, N.A. Shub, A.O. Bueverov, N.A. Barsukova, M.V. Kalashnikov, A.YU. Demyanov, O.I. Nikitin

    Chronic hepatitis C (CHC) is a viral disease primarily affecting the liver, characterized by prolonged persistence of hepatitis C virus (HCV) and a high risk of developing liver cirrhosis and hepatocellular carcinoma. Modern direct-acting antiviral agents achieve a sustained virologic response in over 95% of patients, with good tolerability and safety. The aim of this study is to review the characteristics, efficacy, and safety of ravidasvir, a next-generation antiviral drug for the treatment of CHC. The literature search was conducted in PubMed/MEDLINE, Embase, and ClinicalTrials.gov up to August 11, 2025, using the keywords: ravidasvir, NS5A inhibitor, HCV, Hepatitis C, efficacy, safety. The review included phase I–III clinical trials investigating ravidasvir in CHC. Ravidasvir is a pan-genotypic inhibitor of the hepatitis C virus nonstructural protein 5A (NS5A), developed as an affordable alternative to other direct-acting antiviral agents. Ravidasvir has been studied as part of interferon-free oral regimens containing sofosbuvir or danoprevir boosted with ritonavir, with or without ribavirin. Clinical trial results have demonstrated high efficacy of ravidasvir-containing regimens against HCV genotypes 1, 3, and 4, regardless of HIV co-infection, prior interferon-based treatment experience, or compensated liver cirrhosis. Thus, ravidasvir demonstrates high efficacy against HCV and an optimal safety and tolerability profile, making it a reliable directacting antiviral agent for the treatment of CHC, including in hard-to-treat patient populations. Key words: hepatitis C virus, chronic hepatitis C, NS5A protein, treatment, ravidasvir

  • Open Access

    Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy

    by P. O. Bogomolov, N. A. Shub, N. A. Gasilova, A. A. Belyakova, T. G. Lidzhieva, E. A. Kondrasheva, N. A. Barsukova, M. V. Arapova, E. A. Isaeva, S. V. Koblov, et al.

    Aim: to evaluate the significance of a positive polymerase chain reaction result for hepatitis D virus RNA (HDV RNA) in liver biopsy specimens of patients with chronic hepatitis D (CHD) after completion of antiviral therapy (AVT) as a predictor of infection relapse.Materials and methods. The study included 21 patients with CHD who received combined AVT with peginterferon alpha and bulevirtide for 48 weeks, followed by bulevirtide monotherapy for 48–96 weeks, making the total duration of antiviral therapy 96–144 weeks. In all patients HDV RNA became undetectable in serum 24–96 weeks from the start of treatment, with aviremia maintained for at least 48 weeks until the end of AVT. At the end of treatment, all patients underwent liver biopsy to detect HDV RNA in liver tissue.Results. Out of 21 patients with sustained complete virological response (negative polymerase chain reaction result for HDV RNA in serum), 8 (38 %) had HDV RNA detected in liver tissue, indicating that a tissue virological response was not achieved. All 8 patients experienced a relapse of CHD within 24 weeks after discontinuing AVT.Conclusions. In patients with chronic hepatitis D who have achieved a complete virological response in serum, the absence of a virological response in liver tissue (detection of HDV RNA in liver biopsy) is a predictor of relapse, providing a rationale for the continuation of antiviral therapy.

  • Open Access

    Effect of vitamin D receptor activators on serum Klotho levels in 3b–4 stages chronic кidney disease patients: a prospective randomized study

    by Ludmila Yu. Milovanova, Vladimir D. Beketov, Svetlana Yu. Milovanova, Marina V. Taranova, Vasilii V. Kozlov, Anastasiia I. Pasechnik, Vladimir A. Reshetnikov, Tatiana V. Androsova, Mikhail V. Kalashnikov

    Background. High risk of cardiovascular events is among leading problems in chronic kidney disease (CKD). Serum Klotho is supposed to be cardio- and nephroprotective; modification of its levels may be important in CKD. Aim. To evaluate the impact of vitamin D receptor activators (VDRA) on Klotho serum levels in CKD 3b4 stages patients. Materials and methods. Study included 90 CKD 3b4 stages patients who had elevated serum levels of parathyroid hormone (PTH). From them, 47 patients (group 1) started to treat with the selective VDRA (zemplar 1 mcg/day), and 43 patients (group 2) started to treat with non-selective VDRA (alfacalcidol 0.25 mcg/day). At baseline and after 12 months we conducted routine examination, serum Klotho measurement, and broad cardiovascular examination. Results. The patients who managed to maintain a target serum PTH level, had higher Klotho serum level (p=0.037) at the end of the study. Patients who used selective VDRA significantly more often reached the target PTH level (p=0.032), had higher serum Klotho levels (p=0.037), and glomerular filtration rate (eGFR) level (p=0.048) than patients who used non-selective VDRA. In addition, patients treated with alfacalcidol more than 6 months, more often had hypercalcemia (p=0.047) and hyperphosphatemia (p=0.035). Group 2 showed higher: pulse wave velocity (p=0.051), left ventricular myocardial mass index (p=0.033), and more advanced heart valve calcification (p=0.038). Conclusion. Successful parathyroid hormone level control with vitamin D receptor activators was associated with higher serum Klotho, selective agents having shown greater effect. Long-term treatment with selective vitamin D receptor activators may contribute to cardiovascular calcification prevention by modifying Klotho levels.


  • Open Access

    Sarcoidosis and primary biliary cholangitis in a patient with cholestasis

    by M. Yu. Brovko, L. A. Akulkina, M. V. Kalashnikov, T. P. Rozina, T. P. Nekrasova, V. I. Sholomova, D. V. Konovalov, A. Sh. Yanakayeva, S. V. Moiseev, Янакаева Алиса Шамилевна

    Primary biliary cholangitis and sarcoidosis are both cholestatic liver diseases. Currently, there are no established specific criteria for distinguishing the diseases from each other; diagnosis is based on the anamnesis, as well as the results of physical, laboratory and instrumental examination. The case report presents a female patient with a rare combination of histologically verified liver sarcoidosis and primary biliary cholangitis. Despite the similar clinical manifestations, the approaches to the treatment of these diseases are completely different, that underlines the importance of the differential diagnosis to exclude combined liver damage.